^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TNF inhibitor

    Related drugs:
    1m
    Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia (clinicaltrials.gov)
    P=N/A, N=240, Not yet recruiting, Riphah International University
    New trial
    |
    HBB (Hemoglobin Subunit Beta)
    |
    thalidomide • hydroxyurea
    1m
    GEMINI: Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=60, Recruiting, Sarcoma Oncology Research Center, LLC
    New P2 trial
    |
    gemcitabine • thalidomide • mitomycin
    2ms
    Tumor necrosis factor inhibitor-related autoimmune disorders in pediatric rheumatology practice: a multicenter nationwide study. (PubMed, Pediatr Rheumatol Online J)
    Among TIRAIDs, non-infectious uveitis and PP were the most frequently observed manifestations, predominantly occurring during etanercept treatment. Disease activity tended to increase during the onset of TIRAIDs. Discontinuation of TNF inhibitor therapy and switching to another biological treatment may be effective in achieving clinical remission.
    Journal
    |
    CRP (C-reactive protein)
    2ms
    Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in Children (clinicaltrials.gov)
    P4, N=90, Completed, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting --> Completed | Trial completion date: Dec 2024 --> Jan 2026 | Trial primary completion date: Jun 2024 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    thalidomide • hydroxyurea
    2ms
    Transcriptional immune programs underlying inadequate response to tumor necrosis factor inhibitors in ankylosing spondylitis. (PubMed, Clin Immunol)
    We identified candidates with repurposing potential for TNFi-IRs. These findings reveal crucial therapeutic targets spanning genes, transcription factors, pathways, metabolites, and cell-cell communication signaling for bench-to-bedside investigation.
    Journal
    |
    IL10 (Interleukin 10)
    2ms
    2025.36: Discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors (2026-525316-33-00)
    P4, N=202, Not yet recruiting, Sint Maartenskliniek Stichting
    New P4 trial • Head-to-Head
    |
    leflunomide • Simponi (golimumab)
    2ms
    Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer. (PubMed, Oncol Res)
    Clinically validated examples include thalidomide analogs that recruit cereblon (CRBN) to degrade IKAROS family zinc finger 1/3 in multiple myeloma, and arylsulfonamide-based MGDs that promote the degradation of RNA-binding protein 39 in acute myeloid leukemia and solid tumors...By integrating multidisciplinary discovery strategies with translational oncology, the field is moving toward the development of next-generation MGDs with enhanced specificity, broader substrate scope, and improved resistance profiles. This study aims to elucidate how these innovations expand the degradable proteome and establish MGDs as a cornerstone of precision cancer therapy, thereby redefining the boundaries of drug discovery and providing customizable degraders tailored to diverse cancer contexts.
    Review • Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    thalidomide
    2ms
    ELV001-201: A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY) (2025-524005-32-00)
    P1/2, N=95, Not yet recruiting, Elevara Medicines Limited
    New P1/2 trial
    |
    CRP (C-reactive protein)
    2ms
    Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction (clinicaltrials.gov)
    P2, N=45, Recruiting, Medicines Development for Global Health | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> May 2026
    Enrollment open • Trial initiation date
    |
    thalidomide
    3ms
    ELV001-201: A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY) (2025-524005-32-00)
    P1/2, N=24, Not yet recruiting, Elevara Medicines Limited
    New P1/2 trial
    |
    CRP (C-reactive protein)
    3ms
    Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=306, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    lenalidomide • thalidomide • melphalan
    4ms
    A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY) (clinicaltrials.gov)
    P2, N=180, Recruiting, Elevara Medicines Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CRP (C-reactive protein)